PubMed · 2013 · 14 citations · 17 references
Open access
MedicineNeurologyPharmacotherapyClinical NeuroscienceNeurologic PharmacotherapyNeurorehabilitationAcute Ischemic StrokeAcute Stroke ManagementCerebrovascular DiseaseNeuroprotectionStrokeStroke PharmacotherapyAcute Ischemic Stroke ManagementAcute Ischemic Stroke TreatmentBolus Intravenous DosingIntravenous Bolus InjectionNeuroimaging Of Ischemic StrokeNeurologic Deficit AssessmentStroke NeuroprotectionStroke Severity Scales
BACKGROUND: Ischemic brain strokes consisttwo-thirdsof strokesand their complications bear a lot of disability for patient and society. In this study, we seek for effect of Erythropoietin on ischemic brain stroke's outcomes according to National Institutes of Health Stroke Scale (NIHSS) changes. METHODS: This study is a RCT (randomized clinical trial). All patients with focal neurologic deficit with primary suspicion of brain stroke undergone neuroimaging evaluations. After confirmation of new ischemic brain stroke, the patients with inclusion criteria'srandomized into two groups of cases and controls. NIHSS was defined for each patient and all patients received a routine treatment protocol. Erythropoietin 16,000 IU as a bolus intravenous dose was given to case patients as soon as neuroimaging study confirmed new ischemic stroke and continued as 8000 IU each 12 h up to total dose of 56,000 IU during 3 days. Patients re-evaluated at days 14 and 28 and NIHSS was assessed by another neurologist blinded to patient's group. Finally, NIHSS changes of both groups compared with each other's. RESULTS: Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023). CONCLUSIONS: Administration of high-dose erythropoietin in first 24 h can be effective on reduction of ischemic stroke complication. A larger scale clinical trial is warranted.
17
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Hannelore Ehrenreich, Martin Hasselblatt, Christoph Dembowski et al. · Molecular Medicine · 2002 · 1K citations · Full text
Transient Ischemic Attack — Proposal for a New Definition
Gregory W. Albers, Louis R. Caplan, J. Donald Easton et al. · New England Journal of Medicine · 2002 · 842 citations
Medicine, Neurology, Neuroscience +12
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Hannelore Ehrenreich, Karin Weißenborn, Hilmar Prange et al. · Stroke · 2009 · 596 citations · Full text